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Abstract: Epilepsy is a serious neurological disorder which affects every aspect of patients’ life,
including added socio-economic burden. Unfortunately, only a few suppressive medicines are
available, and a complete cure for the disease has not been found yet. Excluding the effectiveness
of available therapies, the timely detection and monitoring of epilepsy are of utmost priority for
early remediation and prevention. Inability to detect underlying epileptic signatures at early stage
causes serious damage to the central nervous system (CNS) and irreversible detrimental variations
in the organ system. Therefore, development of a multi-task solving novel smart biosensing
systems is urgently required. The present review highlights advancements in state-of-art biosensing
technology investigated for epilepsy diseases diagnostics and progression monitoring or both together.
State of art epilepsy biosensors are composed of nano-enabled smart sensing platform integrated
with micro/electronics and display. These diagnostics systems provide bio-information needed to
understand disease progression and therapy optimization timely. The associated challenges related
to the development of an efficient epilepsy biosensor and vision considering future prospects are also
discussed in this report. This review will serve as a guide platform to scholars for understanding
and planning of future research aiming to develop a smart bio-sensing system to detect and monitor
epilepsy for point-of-care (PoC) applications.
Keywords: nanotechnology; biosensors; neurodegenerative disorder (NDD); diagnostics;
analytical tools; diseases management
1. Epilepsy as CNS Dysfunction & Therapeutic Challenges
Globally, among the serious neurological disorders, epilepsy is the most common disorder and has
been ranked fourth in the United States of America (USA) just after migraine, strokes and Alzheimer’s
disease. Presently, despite medical advancements and progress in new therapies, the heterogeneity and
complexity of the disease affect more than sixty-five million people worldwide (as per the World Health
Organization (WHO)), one-third of which have uncontrolled seizures [1,2]. Epilepsy is a neurological
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condition that affects individuals irrespective of gender, social, geographic, and racial boundaries [3].
This is not a single ailment but rather a package of many symptoms which are the indications
of underlying brain dysfunctions. The chronic disorder is caused by an aberrant dynamism of
neural networks generating anomalous synchronically discharging neurons, thus, leading to recurrent
spontaneous seizures with multi-factored etiology [4]. Significant neuro-pathological changes in the
hippocampus, variations in consciousness, poor motor coordination abilities, comorbidities, stigma,
and other brain functions are few of the common symptoms [5,6]. Apart from the lack of essential
potent drugs, incompetent drug delivery systems, and timely sensing of this illness has been the
significant drawback towards the development/optimization of appropriate therapy [7]. A continuous
understanding of epilepsy causes and classification, more than 50% remittance cases, and medical drug
resistance lead to prognosis and therapeutic complications [8]. The onset of most seizures (focal or
generalized) and their consequences (automatisms, behavior arrest, hyperkinetic, autonomic disorder,
impaired cognition, and unawareness) have been related with the CNS insults and impaired mental
health conditions.
Clinical and animal studies have indicated the breakdown of the blood-brain barrier (BBB) as
one of the prominent reasons in most cases of epileptic seizures, either caused by some accident
or neuronal dysfunctions [9]. Further, enhanced micro-pinocytosis, basal membrane thickening,
fewer mitochondria in endothelial cells, and the presence of abnormal tight junctions have been
considered to be other related causes which are diagnosed by ultra-structural studies of epileptic
tissue in humans [10]. Various injuries, lesions or surgeries which accidentally defect the BBB support
the hypothesis of triggering events causing epilepsy and numerous cognitive impairments [11,12].
The presence of ions like Fe2+, Ca2+, and few others in the extracellular space or release of such ions
(such as releases Fe2+ ions, hemoglobin (Hb) from erythrocytes) after an injury or trauma can enhance
the neuronal damage through production of hydroxyl free radicals, deoxyribose, and deoxyribonucleic
acid (DNA) degradation (Fenton reaction). The reactive oxygen species (ROS) generated, in turn,
inflict the healthy neurons to become epileptic which promotes the disorder (Figure 1) [13,14].
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infectious, metabolic, immune, and other factors. However, still many types of seizures are kept in the
unclassified section for further research investigation [15].
An epilepsy incident is considered treatable, pertaining to its timely diagnosis, clinical proficiency,
and level of seriousness. The predictability of seizures, co-ordinates of epileptic focus, and proper
monitoring could prevent the sufferings, casualties, and improve the morbidity in patient’s life [2,16,17].
The advancements in sensing technologies can overcome these obstacles in order to timely identify
the focus of epilepsy. For appropriate sensing, detection, and diagnosis of a disease, highly selective,
and precise biomarkers are the most essential weapons. In Figure 2, various biomarkers for epilepsy
are summarized. If analyzed systematically then these recommended parameters individually or
collectively can be associated with epilepsy.
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Further, these biomarkers when combined with a vision of nanotechnology’s effect, miniaturization of
devices, and associated synergism can result in smart epilepsy management. The hybrid theranostic
units can help in finding unfathomed mechanisms of the disease at molecular and cellular levels as
well as deals with the imprecise epidemiology [19,20]. Unraveling the exact mechanisms and pathways
can help in curing the disease and prevent sudden unexpected death in epilepsy (SUDEP). Table 1
gives an overview of the epilepsy types and related biomarkers which help in the prediction of the
onset or ongoing seizures [21].
Table 1. Different types of seizures and related changes in biomarkers.
Seizure Type Symptoms and Associated Biomarkers
Tonic Muscles contractions (Seconds to minutes) associated with body movementand sweating.
Epileptic spasm Flexion, extension of proximal muscles, and sweating. Occurs in clusters.
Dystonic Contraction and twisting of agonist and antagonist muscles, and abnormalposture.
Myoclonic Sudden low amplitude contraction(s) of muscle(s)
Negative myoclonic Inconsistent tonic muscular activity (<500 ms)
Clonic High amplitude semi rhythmic muscle movements associated with sweating
Atonic Sudden loss of muscle tone involving head, trunk, jaw, and limbs
Generalized tonic-clonic
seizure (GCTS)
Tonic contractions along with the clonic movement of somatic muscles along
with sweating
Focal dyscognitive seizure Disturbed cognition, perception, emotion, and executing parametersassociated with body movement and sweating
Non motor Ictal phenomenon creating sensory seizures/functions
Autonomic Variation in the CNS, cardiovascular, pupillary, gastrointestinal, andthermoregulatory functions
Overall, diagnostics of epilepsy type or seizures occurring, and identification of active region
during illness, through advanced technology has been the most prominent and active area of research
which is pivotal for therapeutic remediation and prevention of diseases [22]. As first-in-humans,
a pilot study by Pati et al., [23] for finding alternative treatments in focal epilepsy which do not
respond to medications revealed the active role of anterior thalamic nucleus instead of the cortex.
So, neurostimulation of the thalamus instead of cortex would open a new avenue of research and
would avoid other cognition interferences due to stimulation of cortex. The EEG and brain recordings
helped in the development of a validated algorithm that can interpret the initiation of seizure-like
electrical activity in the thalamus or vice-versa. All this eventually lead to the development of new
and advanced biosensing devices.
Keeping advancements and challenges in view, the understanding of the state-of-art analytical
devices which can be used for the detection is very important for epilepsy management and is the
focus of this review. The nanotechnology assisted advanced sensing systems, research outputs existing
in the market, and other systems capable in detecting and monitoring epilepsy are focussed.
2. Analytical Tools for Epilepsy Detection
In order to understand the actual neurological condition and to avoid garbage in–garbage out
(GIGO) process, therapeutics have to be amalgamated with the real-time sensing platforms [24].
Cognitive testing and neuroimaging have been performed using various analytical techniques to
detect epilepsy-related abnormalities. However, apart from these, EEG is considered as a gold rated
and most standard analytical technique for epilepsy diagnosis and detection. The EEG records the
neuronal cell potential using scalp electrodes. Commonly, painful, piercing needle electrodes are used
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in conventional EEG. Quantitative EEG (qEEG) is another advancement over conventional EEG which
maps the electrical activity of the brain using more than 24 electrode systems. This mapping using
qEEG is also termed as brain electrical activity mapping (BEAM), where the data is mapped over a
brain image with different colors and shades and has been cleared as a class II medical procedure for
clinical practice. The amplitude-integrated EEG (aEEG) is generally used to measure the electrical
activity in the cerebral cortex for a more extended time period, say for days. The electrode is placed
on the scalp, and the variation in the electrical signals can be interpreted in events such as epileptic
seizures. High activity on the chart indicates the event of a seizure, which would have been seen as a
normal waveform in the absence of an integrated platform. The basic idea involved in all the EEG
platforms is charting of the electric variation in the brain using the voltage of neurons. The comparison
between the electrical activities, i.e., voltage fluctuation due to ionic current within neurons of the
brain normally and before, during or after seizure using electrode placed along or drilled into the scalp
defines the agitated area of the brain [25,26]. The poor spatial resolution, noise, and use of complex
parameters (skull radius and specific electro-conductivity) are mostly worked out for analyzing the
neural activity of cortex. Their use in research field is still fundamentally important which is produced
to forward an idea about the statistical proof of the concept [27].
MRI is another remarkable technique which views the anatomical structures, using hydrogen
nuclei of the water molecule inside brain tissue. An MRI does structural imaging to differentiate
between tissue types, providing high, spatial resolution images. However, the inability of MRI to
register metabolic functions leads to the generation of functional MRI (fMRI). The fMRI technique
uses oxygen levels to study the changes over the hydrogen nuclei of water molecules in MRI and can
differentiate between tissues with respect to time. The superior long-distance temporal resolution of
fMRI offers an advantage over MRI. Since its inception in 1992, fMRI use has amplified like an outburst
to become one of the most trusted neuroscience tools. Diverse animal brain regions can be imaged
for transformed electrical activity of neurons. Above all in fMRI the functional brain image can be
obtained using cerebral arterial blood flow changes with spin labeling [28–30], oxygenation levels of
the neuronal blood [31,32], cerebral blood flow volume [33,34] and few other mechanisms. However,
apart from research activities for most of the diagnostic purposes, MRI is preferred over fMRI due to
the complex nature and economic constraints. Today newer techniques are shaped integrating two or
more primary techniques to get synergistic benefit in diagnosis and treatment. A combined hybrid
integrated technique, like fMRI combined with EEG, has been able to mark the focus of epilepsy for
the non-detectable epilepsy form by measuring the blood oxygen level dependent signal, indicating
inner variations in the neurophysiology. The fMRI integrated with EEG (EEG-fMRI) has become
instrumental in mapping the origin of epilepsy and neural activities [35,36]. Precise detection of the
epileptogenic zone can be analyzed using EEG-fMRI using a deep learning semi-automatic interictal
epileptic discharge (IED) detector based epileptic discharge detector [36].
Techniques like PET, ictal single-photon emission computed tomography (SPECT), MRI,
and optical coherence tomography (OCT) have further revolutionized investigations of epilepsy [37,38].
In PET scan, the patient is injected with a minimal amount of radioactive tracer which gives out
signals in the form of positrons that merges with the negatively charged electrons within our body.
The interaction of positrons and electrons is used to make an image. Brain’s use of oxygen and
glucose is the fundamental point which this scan shows. This relation of seizure activity with glucose
uptake and release of glutamate can be also be measured by fluorescent deoxyglucose and thus,
is an important aspect for determination of seizure foci [39,40]. The advanced form of PET is SPECT,
an imaging method using nuclear medicine which measures regional cerebral blood flow (rCBF);
based on the principle that partial seizures are associated with an increase in rCBF [41]. In ictal
SPECT a photon emitting radiotracer is injected when a seizure marks its onset, later the patient
is scanned after the epileptic episode using a rotating gamma camera to obtain SPECT images,
providing a three-dimensional image. Another non-invasive method technique, functional NIRS
(fNIRS), has proven its advantages over SPECT in detecting an epileptogenic focus and neural
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behaviors [42]. Further, OCT is a label-free, minimally invasive imaging tool, with very high temporal
and spatial resolution and dual optical contrast [43–45]. It provides a cross-sectional view of the retina
inside the eyes with an accuracy of 10–15 microns, using the concept called interferometry. Initially,
this technique was developed to be used in ophthalmology only but later found its use in epilepsy
research. OCT is now utilized in patients using vigabatrin (a potent anti-epileptic drug) to assess their
retinal thickness, to find its inter-relation to epilepsy duration, severity, drug resistance and localizing
the focus of epilepsy inside the brain. The intensity of infrared light decreases in cerebral cortex tissue
during as well as after generalized tonic-clonic seizures induced by pentylenetetrazole (PTZ) [46].
When used in rats, proved that near-infrared light could record seizure development [47]. It has helped
identify perturbations in the cortical tissue, before and after a seizure by generating excellent clarity in
brain images. It is an optical analog of ultrasound imaging with the ability to generate cross-sectional
image of tissues by measuring the time and intensity of reflected light. The possible measurement
of modulation in optical scattering and coefficient of reflectivity of the tissues with surrounding
epileptic neurons helps in accurately predicting real time brain imaging and functioning modality.
After successful clinical retinal and vascular diagnostic imaging the same principle of sensitivity to
NIR scattering has been extended for imaging of in vivo cerebral cortex. The experiment gives the
proof-of –concept for successful implication of OCT for non-invasive detection of pre-ictal state on
clinically relevant timescale [45,48]. Due to dual optical contrast, the collective measurement data
of OCT measurement along with hemodynamics during the event of epilepsy using photoacoustic
microscopy (PAM) helps in epilepsy mapping with high special resolution [43]. Further, label free
detection of the vascular changes in the hippocampus within deep brain areas of mice have been
visualized using 1.7 µm swept source OCT system to identify the blood flow changes during brain
diseases and probable understanding of underlying mechanism [44].
The correlations among various vital organ behaviors with epilepsy are also significant to detect
minute processes in motion. Figure 2 gives an overview of biomarkers which can be associated with
epileptic seizures. Reports suggested that the short or long term neural disturbances can alter the
heart rates and can even cause unexpected death [19]. Tachycardia and Bradycardia can also be
related to the anomalies in the right insular cortex and temporal lobe epileptic seizures respectively.
The correlation between the changes in brain and heart has been analyzed by ECG [49,50]. In order to
detect minute subtle seizures in newborns and neonatal intensive care units, EEG suppression due to
postictal hypotension can act as an indicator for the disease. Whereas, magnetoencephalography (MEG)
allows us to evaluate the functional connectivity of brain networks through variation in the spectral
pattern throughout the complex network. MEG is a more potential and facile method compared to
EEG for determination of the focal point of epilepsy, as skull and scalp do not attenuate magnetic
fields [51]. Routine MEG results can be overlapped for a broader understanding and have been seen
to be correlated with other detection techniques (MRI, PET, ECoG, etc) [52]. The bio-magnetometer
in this regard has further enhanced the imaging and eliminated the conventional limitations of this
technique. Similarly, video detection systems like night vision cameras and mattress sensors connected
with alarms, microphones, smartphones, watches, big screens, and digital timers can monitor the
trajectories and frequency of the seizures. These devices can also be used for continuous long-term
monitoring of movement patterns or physiological variables, rhythmic repetitive movements during
the seizure. The motor seizures (tonic-clonic or myoclonic seizures) and related movement variations
can easily be detected and patterned for personalized therapeutic applications. Such systems detect
around 95% of the motor seizures. Whereas, accelerometers (ACM), video, and mattress sensors are
more effective in the detection of seizures associated with the motor phenomenon. The continuous
utilization of such devices for charting anxiety and depression, with the help of electro-dermal activity
(EDA), heart rate variability (HRV), and heart rate monitoring (HRM) have become more and more
common for neurological disease management, but conspicuous wearable and associated stigma is
another issue to overcome. A device was proposed for mobile phone based application and wearable
RRI (RR interval fluctuation) sensor for predicting real time seizures, capable of resolving “preictal”
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and “interictal” seizures using HRV [53]. The statistical analysis of HRV and its correlation with
neural anomalies can effectively predict or measure the pre-ictal seizures [53]. The results can be
utilized for development of algorithms which can easily predict or characterize the epilepsy seizures.
These techniques are not very specific and can also be used for the detection of other seizure types
with different sensitivity. Individual sensing techniques EEG, EDA, near-infrared spectroscopy (NIRS)
utilized to detect focal dyscognitive seizures exhibited limited applicability and sensitivity, whereas,
the combinational approaches such as implanted advisory systems and ECG have good sensing of focal
seizures. In comparison to individual detection techniques, the multi-modular sensing approaches
have seen to be more effective. Few individual techniques and their synergistic combination with
others for epilepsy management have been shown in Table 2 [54]. The lower degree of specificity for
detection of seizure type can be worked upon in the near future.
Table 2. Sensitivity of individual and multimodal systems for specific types of seizures.
Technique Sensitivity (%) Seizure Type Ref.
Intracranial EEG 80–98.8 Focal seizures
[54]
Scalp EEG 74–96.6 Focal seizures
EDA 86 Focal dyscognitive seizures
ECG 70–99.8 Focal seizures
Accelerometry 95.71 Hypermotor seizures
Video detection system 93.3–100 Motor/Hypermotor seizures
EDA and ACM 94 Motor seizures [55]
sEMG and ACM 91 Tonic-clonic seizures [56]
Magnetometer and ACM 62 Tonic seizures [57]
Magnetometer and ACM 90 Tonic clonic [57]
VARIA: Video, ACM and
Radar-Induced Activity
recording
56 Generalized [58]
EEG and EKG 92 Tonic clonic [59]
NIRS 94 Hemodynamic responseduring seizures [60]
MEG
MEG/EEG
60
71 focal or generalized epilepsy [61]
3. Nano-Bio-Sensing Regime Remediation
A major drawback of present epilepsy control scenario involves improper follow-up on the
number of seizures, the efficacy of anti-epileptic drugs (AEDs), supportive medicines, real-time
analysis of changes in the physiology, behavior, and chemicals in the system [24]. The advancements
in nano-biotechnology have made the real-time analysis of epileptic patients possible, using miniature
implantable/or wearable devices in the form of wristbands, anklets, capsules integrated into clothes
with advanced nano-enabled sensors [62–66]. Such personalized epilepsy care (Epi-Care) devices rely
on the pattern and character recognition algorithms, connected to smartphones, laptops and other
devices. The algorithms are developed based on the changes in motion trajectories, with respect
to time, space, velocity, angular speed, and other factors. The basic principles are primarily
taken from electroencephalogram, accelerometer, electromyograph, gyroscopes, magnetometer,
and electrochemistry, which analyses the changes in acceleration, velocity, directions, ionic current,
and electrical activity of the brain in the three-dimensional system [67,68].
Different types of seizure are detected using a specific type of sensors. Finding the main legitimate
component character of the seizure is the most elementary and beginning step towards choosing
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an appropriate seizure detection sensor device. Two such components used to evaluate the seizure
are physiological signatures and movement patterns. Physiological signatures include temperature,
heart rate, sweating, respiratory rate, and other physiological parameters. Wherein the temperature
change could be detected using wristband, heart rate change by electrocardiogram, sweating by
electrodermal activity (EDA), and respiratory rate change by the use of thoracic bands. Movement
patterns of various body parts like the eye, head, limbs, can be detected using the accelerometer, EMG,
seizure alert dogs, video-mattress monitoring sensors, and electrooculogram. Ideally, the best seizure
sensor would possess the ability to detect both physiological as well as movement cues rendered by the
patient. Nanotechnology-enabled biosensors emerged as potential analytical devices for early-stage
diseases diagnostics, therapy optimization, and customization of personalized therapeutics [69,70].
Pooling sensor-based data clues for a long time can help in forecasting seizures for specific individuals
and particular triggers behind them. Nanobiosensors enable quantification of biomarkers such as
dopamine (DoP), uric acid, ascorbic acid, hypoxanthine, acetylcholine, glutamate, lactate, and glucose
which can be useful to correlate the neurochemical secretions with epilepsy [68,71–73].
It is expected that nano-intervention into EEG and ECoG, will make the most reliable methods
of seizures detection, even more, improved for clinical use. The use of conventional electrodes for
recording is accompanied by problems like the discomfort of displacement and irritation by their
mere presence [75,76]. Recently, nanotechnology has opened up newer avenues for the fabrication
of portable, wireless, wearable EEG monitoring device over conventional electrode system as shown
in Figure 3 [74]. The small EEG platform is ambulatory and integrated into a wearable headset
or headband. The traditional EEG uses invasive, penetrating electrodes and gels for better signal
conduction, on the other hand, the newer portable nano-enabled EEG is non-invasive, does not need
the use of conducting gels and is devoid of noise and uses less power. The new EEG comes in the
form of a headband with a dry electrode sensor for potential quantification applications (commercial
name ENOBIO) designed to eliminate interfering noise disturbances and electrolytic gel associated
inconveniences. The electrode contact surface is made up of carbon nanotubes (CNT), coated or
uncoated with silver for better conductance and precise potential transfer. The carbon nano-tubes
penetrate the outer layer of skin, for better potential signal transfer.
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Figure 3. Schematic of (A) neural signals ( EGs, ECoGs, LFPs, and spikes) a t eir r erties. (B) EEG
electrode on the skull, ECoG electrode on the surface of brain, and penetrating electrodes: three main
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This led to the construction and integrati n of a sophisticated technique like EEG into a simple
h adgear and made th detection of epilepsy in chronically ill p tients effortlessly uncomplicated [77].
For furthering the research and using the CNT array dry electr des, in a human r search trial,
for rec rding t biological pot tial of neurons was conducted. This nanotechnology derived el ctrode
or sensor improved the wearability, effectiveness, and accuracy for use by the patients. Additionally,
Sensors 2019, 19, 1525 9 of 28
its use caused less irritation, being devoid of the use of conducting gels and surgery to implant
painful electrodes, invasively on the skull. The critical aspect of this model was the skin-nanotube
electrode interface juncture, in which a large number of multi-walled CNTs (MWCNTs) worked like
brush bristles to provide with anchorage and link for better potential transfer, from the brain to the
recording device. The MWCNTs were chosen to be used in the electrode because of its immense
mechanical character indicated by high elasticity modulus, tensile strength [78]. Moreover, MWCNTs
have excellent conduction and electrical properties. This nanotechnology-based architecture endows
the device with a steady, powerful electrical transmission devoid of aberrations pertaining to noise
and impedance. Additionally, this EEG module is painless, hardly punctures the outer skin coat of
the head region called as the stratum corneum, hence no need for skin healing and wound care at
the site of electrode placement and thus is very convenient to use. Due to the narrow diameter of the
MWCNT and slight insertion of the electrode, it would be a scar to seal and heal up infection less,
which is not the case with the routine EEG procedures. However, the nanotechnology influenced EEG
device is beneficial but its fabrication is both multidisciplinary, involving the in-depth expertise in
nanobiotechnology, and complex. Bigger holes on the scalp, use of liquefying gel for conductance
enhances noise and thus may result in misleading seizure data in the standard EEG procedures but
not when using the nanotechnology version of the EEG. In the latter case, the advantages attributed
to MWCNT which showed the special nano-bio interface formed between the nanotubes and the
skin. In this study, the subjects involved in studies did not experience any pain, sensation or irritation
on use of the nano-electrode [79]. It is now used as the first obvious choice of detection for tumors,
sleep disorder, or other in case neuronal strokes before functional MRI (fMRI), computed tomography
(CT), PET.
A method to measure the kinetics of omnipresent calcium ions, which play diverse intracellular
and extracellular roles in the body, was developed using magnetic calcium responsive nanoparticles,
which can be detected using MRI. These nanoparticles are proven to respond to the slightest variations
in calcium concentration, which can detect brain activation and thus help us map brain dynamism for
nanoparticle-based sensors for molecular imaging with MRI [80]. The resolution of MRI can be further
improved by using nanotechnology-based contrast agents like the use of superparamagnetic iron oxide
(SPIO) nanoparticles, unique ferrimagnetic vortex iron oxide nano-rings (FVIO), and calcium-sensitive
calmodulin, etc [80–86].
Other analytical techniques can be used simultaneously for the detection of biomarkers for
epilepsy, like hormonal changes, neurotransmitter, and extra-ocular movements. The concentrations of
neurotransmitters and modulators in the extracellular space are of great importance and can only be
measured directly by few techniques (antibodies, PET, microelectrode biosensors, mass spectroscopy
of tissue sections) [75,87–89]. The results from the carbon nanotube-based microelectrode system
have better resolution than conventional neurochemical sensing systems, it allows efflux detection
of endogenous neurotransmitters and overcomes the limitations of electrophysiological techniques
(Figure 4) [75]. The changes in physiological fluids after seizures also project a qualitative analysis such
as elevated serum lipid peroxidation (SLP), reduction in vitamin C and variation in the concentration
of ions. The intracellular nano-sensors composed of quantum dot injections, magnetic nanoparticles
or tethering of nanobiosensors to brain cells, such as ion-selective sensors for detection of Na+, K+,
Cl−, Ca2+ ions and others for identification of brain disorders are prevalent [80,90]. The in vitro
process works in the cytoplasm of a living cell, where the nano-sensor detects the ions by the selective
polymeric ion-exchange process. The change in ionic concentration, leads to a pH difference within
the sensor and triggers the color change of pH-sensitive dye or ionophores and hence, the absorbance
or fluorescent intensity is observed [91].
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Figure 4. Structure and modification of microelectrode array (ME ). ( ) Silicon-based MEA with
four shafts [92]. The 16 round sites were used as recording sites to detect electrophysiological and
electrochemical signals, and the three rectangular sites were used as auxiliary sites in the three-electrode
system. (B) The electrophysiological recording sites are modified with PtNP and glutamate recording
sites have three different layers (PtNP/mPD/Gluox) modification. The thicknesses of PtNP layer
and the enzyme layer were 3.2 and 1.5 µm, respectively. (C) The AFM photograph of the surface of
Gluox enzyme layer. Surface irregularities make Gluox more accessible to glutamate. (D) The physical
view after package, the size of this sensor is close to the pencil head and the weigh is about 1 g [68].
(Reproduced here with copyright permission [68]).
Neurological disorders such as epilepsy are considered to be triggered due to lowering of DoP
concentration as it regulates various vital neuronal functions within the brain and body. Specificity
of the interaction (electron transfer, inner filter effect, pi-pi stacking) between the electrode and
analytes makes it capable for simultaneous specific determination of biomolecules like DoP, uric acid,
ascorbic acid, tryptophan for quantitative and or qualitative analysis [93]. Reproducibility, robustness,
and specificity exhibited by such techniques are very important for the long and real-time analysis of
neurotransmitters. The DoP concentration was detected using various sensors based on electrochemical
techniques through nanoparticles and quantum dots [94,95].
The graphene-based transistor was reported for the recording of in-depth neural activity along
with the changes on the surface [96]. This intracortical probe works dually to probe both surface
and in-depth neuronal activity. The high conductance, flexibility, mechanical strength and chemical
stability of graphene makes it an ideal material for such applications over other reported metal or
silicon-based probes. Some of the conducting polymers used and their nano-bio-composites with CNT,
graphene, etc., the based probe was fabricated to detect neurotransmitters as shown in Figure 5.
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Neuro-electrical interface implants are developed for deep brain stimulation (DBS) comprising
another class of novel nano-devices called the neuroprosthesis. Presently, in studies with rats and
monkeys it uses electrodes made of noble metals coated with CNTs [98]. Efforts are being made to
incorporate computational data analysis to the DBS implants for precise electrode placement and
stimulation optimization [99].
Nanostructures such as gold (Au), graphene, CNT and quantum dots sandwiched or combined
with biopolymers such as chitosan, polyethylene glycol, etc.-based biosensor was designed and
developed for detecting biomarkers such as GABA (γ-aminobutyric acid)/glutamate, purine, ATP,
and adenosine [100]. The biopolymers have high permeability, good adhesion, reduced or no
toxicity, and can be reused again after simple procedures. The use of conducting polymers in
electrochemical sensors have an added advantage as they can simultaneously increase the stability of
the electrode by encapsulating the same and increasing the conductivity and surface area for sensing
applications [97]. Neurotransmitters such as 3,4-dihydroxyphenyl ethylamine (DoP), glutamic acid,
histamine, acetylcholine, choline, and other neurochemicals control learning, emotions, sleep, cognition,
behavior, consciousness, mood, etc., through transmission of neuronal signals. As the sensitivity of
sensors helps in detection of physiological changes or fluctuations inside the body, which in turn
depends on the properties of constructing material or mediators like aptamers, micro/nanoelectronic
mechanical systems (MEMS and NEMS), nanoparticles, quantum dots, and polymers. Thus, the type
of material used also plays a vital role in designing an appropriate technique. The biopolymeric
materials with intrinsic flexibility, biocompatibility and conductivity are associated with the specific
functionalization of nanostructures and can pave the path for next-generation sensor materials in the
long run.
4. State of the Art Epilepsy Bio-Sensing Techniques
A well-recognized expansion is observed in the newer, advanced, and better than ever
nanotechnology modules, invented in the existent times for enhancing epilepsy cure and care.
Nanomaterials including organic polymers, inorganic nanomaterials (nanomembranes, nanotubes,
nanodendrimers), and their hybrids are being developed for bypassing BBB, sensing, and delivering
therapeutic drug on demand [101–103]. Nanomaterials that respond to externally applied physical
stimuli such as temperature, light, ultrasound, magnetic field and electric field have shown great
potential for controlled and targeted delivery of therapeutic agents. Controlled drug release and
targeted delivery of therapeutic agents have been achieved by implication of bio-nanotechnology,
electrochemistry, advancement in neuroscience, and modeling of neuronal circuits. In this regards,
Sensors 2019, 19, 1525 12 of 28
quantum sensing systems were investigated for ultrasensitive detection in the nanoscale resolution
which requires control over a few quantum bits (qubits) [104]. Similar to quantum computation,
the sensing initialization, control and readout of qubits. The strong foundation of quantum
computation has made it feasible to measure few qubit systems (spins in diamond) and their coupling in
physical environments (live cells) with excellent quantum coherence at room temperature. These optical
quantum sensing with high sensitivity can be employed for nanoscale systems, cellular dynamics and
brain. A research group has demonstrated an optimized study of spatiotemporal distortions using a
two-photon system [105]. These interdisciplinary sensing techniques have vast applications ranging
from condensed matter physics to cellular dynamics. Still, a long way to go but biophotonics can be
the key technology for ultrafast and non-invasive sensing ability in future [106–108]. The molecular
plasmonics which studies the interactions between the molecules and surface plasmonics have shown
great importance in the field of nanomedicines and biology. The excitation of surface plasmon
can confine electromagnetic field which generates localized thermal energy and large near field
optical force. A non-destructive method has been developed to monitor neural activity based on
excitation of surface plasmon resonance (SPR) over Au structure-coated optical wires. Laser light
is used for excitation of plasmons over the thin film of metallic Au. The absorbance of light by
SPR of the metallic surface is dependent on dielectric properties of the vicinity. The neural activity
(action potential) can modulate the dielectric properties as well as SPR of the metal surface and
absorbance of light in the optical fiber. Based on the different geometrical structure of the brain,
the sensor show absorption in the different region of visible spectrum [109]. The detection of an
epileptogenic focus can be non-invasively performed by NIR. This technique has been found to be better
than SPECT which measures cerebral tissue oxygenation [110,111]. It can be used to measure complex
spatial and metabolic changes, oxygenated-deoxygenated blood and total hemoglobin content during
seizures [66]. Further collaboration and unification of techniques improve localization, detection,
and timely therapeutic administration against seizures.
Mapping of neuronal activity with single neuron resolution has been made possible using
optogenetics and chemogenetics along with genetic targeting for therapeutic purposes [112,113].
The photonic light energy can be used to bypass the BBB through ligand-gated channels along with
protein (opsins) or drug molecules. The electronic imbalance can be simultaneously monitored by
potentiostats and spectrophotometer devices. Sarissa Biomedical Ltd. (Coventry CV4 7EZ, UK),
have developed novel biosensors/microelectrodes such as the sarissaprobe®-ATP, sarissaprobe®-ADO
(adenosine) and sarissaprobe®-INO (inosine), for neuroactive chemicals used during in vivo and
in vitro studies. The same has been used and research studies state the determination of the role of
ATP in electrically-evoked electrographic seizures [114]. Apart from just measuring the concentration,
microelectrode biosensors detected the release mechanisms as well [87].
An umbrella terminology, under neuromolecular imaging (NMI), the BRODERICK PROBE®
nano-biosensor for neurotransmitters is being produced (Broderick Brain Foundation, New York,
NY, USA). It can be used as nanosurgical/imaging device composed of carbon-based substrate
used for diagnostics and or live imaging during surgery or otherwise for neurodegeneration or
status epilepticus or in non-responsive AED therapy. The Broderick probe uses light-sensitive
proteins like opsins to monitor the photoelectrochemical current using a potentiostat, spectrometer,
and/or a spectroelectrochemical chemiluminesence device. It is a slender, compact, hairy thin
neuromolecular imaging nanosensor, which manifests the presence of neuropeptides as a biomarker
for epilepsy. This device consists of a light sensitive, electrically active, protein sensing neuroprobe,
which works by changing photonic energy into electrochemical energy, which can be imaged in
actual time, which can help treat devastating neurodegenerative disorders. This minimally invasive
electrochemical (potentiostat range ±1000 mV, scan rate ~5–30 mV/s) biosensor is unique, used for
in vivo, or in vitro real-time imaging and utilization in numerous arenas. It is utilized to image
neurotransmitters/neurochemicals/neuropeptides (DoP, serotonin (5-HT), homovanillic acid (HVA),
L-tryptophan (L-TP), dynorphin A (DYN A) and somatostatin (SRIF)) intraoperatively during
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neurodegeneration process in epileptic human patients and animal models with/without degradation
by Parkinson’s disease [115,116]. Primarily, this nano-biosensor was built for use in enucleation
surgeries for epilepsy, for patients who were non-receptive to anti-epileptic drug (AED) treatment [115].
Photoacoustic imaging of nanosensor techniques focus on imaging either endogenous signals
such as hemoglobin or exogenous contrast agents such as CNT. Lithium-selective nanosensors are
introduced into mice, and later, with the help of photoacoustic tomography, an image analysis
can be carried out. Importantly, the data collected is for the entire tissue volume and entire
sensor injection, rather than nanosensors lying close to the scalp or skin [117]. Biocompatible
implantable MEA have shown promising results in acquiring data, monitoring the activity in the
brain due to remarkable electrical sensitivity, discharge pattern of neurons, their synchronization,
interictal spikes, local potential and concentration of biomarkers. Silicon-based MEA modified by
platinum nanoparticles can perform a dual work of neural electrophysiology as well as quantifying
neurotransmitter indicating epilepsy [68]. However, sometimes limited to the type of epilepsy under
investigation, photoacoustic Imaging, utilizing the surface plasmon phenomenon of carbon-based
materials or metallic/metallic oxide nanoparticles (CNT, Au and silver nanoparticles) and magnetic
nanoparticles. Surface projection is possible due to its ability to capture the result from the whole tissue
area closest to the skin surface and can be helpful for the measurement of the exact concentration of
effluxed drug across the BBB and its management. This real-time, non-invasive technique can visualize
molecular changes with magnificent spatial resolution inside living tissues [118].
Nano-enabled sensing systems such as wireless e-bra, e-band, other integrated electronics, hats,
and shoes for periodic analysis of neurological disorders, physiological monitoring and other associated
benefits like cardiovascular, motor functionality, sensory neuroprostheses (neural electrical implants)
are being fabricated and worked upon.
Machine learning methodology and computational algorithms are also very important recent
advancement in prediction of seizures before the time, thus, helps in medication of epilepsy.
The identification of new biomarkers and activity points for seizures with automated correlation
of whole brain activity can be worked by computing and machine learning tactics. For example,
EEG signals can used as a foremost detection technique, however, the level of noise and resolution
limits the application. The associated machine learning techniques can do this sorting within few
moments by following a pre-defined models. Various classifications of seizure and non-seizure records
using machine learning to generalize seizure detection have been performed with greater sensitivity
and specificity [119–121]. We think that the accumulation and processing of patients clinical data
(big data) using proper machine learning algorithm along with advancements in nanotechnology holds
an important role in development of future modalities for epilepsy management or other biomedical
diseases [122].
5. Challenges and Future Perspective
The quantification of every time electrical, behavioral and physiological changes have been made
possible using, both external and internal wearable wireless systems such as mood-awareness sensors
wearable on clothes, watches, bracelets, and bands. The changes in cardiovascular and neuronal
activities can also be monitored through EDA, HRV and skin conductivity during epileptic stress [123].
Clinicians have implemented new measures and have treated the ailment from this acquired data.
Nano-sensing regime has helped in the development of chip-based effective implantable and injectable
electrochemical immunosensors, protein sensors, and magneto-electric sensors. These technological
advancements not only improved the detection of epilepsy many folds but also provides remediation in
the form of nanobots, nanoparticles, aptamers, polymersomes, nanocomposites, and nanodendrimers
for possible delivery of available medicines and diagnostic agents [124].
Epilepsy-associated repercussions, i.e., fits, loss of body and its movements control,
sleep disruptions, drowsiness, nausea, cognitive abnormalities, disruptions in many other body
functions and prolonged therapy makes its remediation a matter of grave concern. Profiling of
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epileptic seizures through contemporary technology which has been advanced by the interventions
of nanotechnology is one of the ways out, for managing epilepsy after analyzing particular seizure
data. Such data not only helps in the timely administration of AEDs but are also well accomplished
in predicting and revealing ongoing seizures. Most of the detection algorithms can be comprised of
basic two steps as: (i) identification and quantification of relevant features through the use of various
detection systems, movements, or other biomarkers, and (ii) the setting of a baseline value for models
derived through modern machine learning algorithms. Figure 6 illustrates detection and sensing
techniques with a vision of the effect of nanotechnology, miniaturization of devices, the synergism
of all components and their overall efficiency [125,126]. Detection and timely sensing of epilepsy
can be controlled by taking varied systematic steps with subsequent modifications for customization
according to patients individually.
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The advanced sensing technology has brought remarkable growth in device development such
as lab-on-chip technology for epilepsy treatment and management. The research related to wireless
sensing systems for neurological studies and teleneurology has been rising due to its user-friendliness,
and in hand real-time analysis (Figure 7) [22]. Further, these wireless measurement systems have
various added advantages such as the absence of invasive procedures, infection free, active monitoring,
mobile tracking, and quick database acquisition, for monitoring response and alerting the concerned
authorities for possible remediation. An effective epilepsy drug decreases excitation and increases
inhibition, but the related alterations lead to various side effects and further repercussions like cognitive
impairment, sleep disruption, deterioration of proper motor functioning and unhealthy neurons.
Maintaining a proper impactful concentration of the drug in affected brain parts, to cure and control
the recurrence of seizures has been possible only through proper modification of drug molecules,
BBB and delivery systems. The epilepsy-specific biomarkers and their initiation could be assessed
by external bioimplants, but more detailed impactful information can be gathered through injectable
biocompatible nanodevices [127]. Improvement in the potency of available drugs has also been a great
concern as they show an inability in more than 30% of patients. Furthermore, they tend to act on ion
channels or neurotransmitter systems, compared to altering genes, genome system, molecular targets,
and pharmacogenomics. Thus, a combined theranostics approach would undoubtedly be effective
that promises to simultaneously monitor and also deliver the drug on demand or as per change in
physiological or electric behavior inside the brain.
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Figure 7. Proliferation of teleneurology studies. (a) A graph showing the volume of published studies
of telehealth and care delivery for stroke (grey) and other neurological conditions (orange) from 1992 to
2017, as listed on PubMed. The past two decades have seen a substantial increase in the volume of these
studies. (b) A graph showing the volume of published studies of smartphones (grey) and wearable
sensors (orange) for neurological conditions from 1992 to 2017, as listed on PubMed. Few studies were
conducted before 2015, but the number has since increased exponentially. (c) The number of mobile
broadband subscriptions, globally. A graph of smartphone ownership (measured by a number of global
broadband subscriptions) from 2012 to 2022. Smartphone (Ericsson Mobility Report, 2017) ownership
rates have steadily increased; by 2020, 70% of the world’s population is projected to own a smartphone
(images reproduced from [22] with copyright permission from Nature Review: Neurology).
Advancements in the technology of the future, i.e., nanobiotechnology and device miniaturization,
will help in the development of such desirable implantable biosensor for in vivo applications.
They continuously correlate the EEG activities or spikes and can trigger medication towards the
epilepsy outburst region by infusion pump only on demand, thus, eradicating the further deterioration
of CNS by overdose or inaccurate drug delivery. The inclusion of nanobots, which can carry
neurotransmitters or growth factors such as engineered cells to express and release GABA, progenitor
cells, and neural stem cells which can potentially replace and restore damaged neural tissue have
revolutionized the theranostic arena for epilepsy. New generation AEDs have been developed with
improved efficiency in the past decade but the control over repercussions of the drug, their appropriate
concentration, the ability of the drug to traverse through the BBB and higher drug resident time
inside the brain are a few other matters for concern. Insights into the recurrence of epileptic seizures
and classification based on their initiation will be a challenge for new generation sensors during the
management of epilepsy.
Presently, drug development is based upon unaltered ion channels which
affects the fast synaptic transmission in CNS such as ionotropic glutamate receptors
(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), N-methyl-D-aspartate
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(NMDA), kainate types, metabotropic glutamate receptors), nicotinic acetylcholine receptors,
potassium channels, neuro-peptide receptors, adenosine receptors, and metabolic enzymes. However,
all such drugs are associated with side effects, affecting the normal functioning of the brain and
have failed to tackle the recurrence of seizures in many cases, so sensors based on the identification
of new molecular targets for treatment and genetic modification may be path-breaking in this
arena. As treatments should be directed towards the actual mechanisms of epileptogenesis or
epidemiology, rather than working on unaltered channels or receptors. This may decrease the
side effects drastically and could be used as surrogate endpoints for expedited testing of AED.
Such target specific drugs would not interfere with normal brain functioning, neurodevelopment,
and regeneration in the patients.
Based on bioinformatic algorithms, sensors based on genomics and subsequent drug release
can be another significant advanced approach. These bioinformatic sensors can be very helpful
in the management and classification of epilepsy through screening the particular targets with
available drug compounds outside the body (in vitro or cell-based) using gene targets and functional
assays. Another important aspect is the promotion of pharmacogenomics, which can produce
drugs customized for specific patients with a particular genome type. Thus, gene chips sensor
technology can be more effective in patients affected by genetic polymorphism (metabolizing
enzymes, transport proteins, genetically-driven aspects of pathogenesis or host susceptibility), where,
generalized medication would not work. The aspects of early-stage epilepsy diagnostics at PoC
application are illustrated in Figure 8. Whereas, the overall toxicity of metal nanoparticles, electrodes in
Epilepsy treatment is a crucial question. So, increasing the biocompatibility of the metal nanomaterials
used should be increased to ensure the safety of human health. Green synthesis techniques can
play a pivotal role in increasing the biocompatibility and making the metal nanomaterials safer for
human use.
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A methodological treatment through early detection, live monitoring, and data analysis,
followed by drug delivery, have magnificently improved the theranostic approach towards
neurodegenerative diseases. These PoC clinical treatments can improve and prolong the life for
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epileptic patients, and also greatly reduces the medical care costs, especially for chronically ill
patients [128]. However, the idea is comparatively nascent and in the early stages of its ontogenesis, so,
it needs more time, research inputs, and standardization for development into a completely seasoned,
improved theranostic model and treatment regime.
Table 3 summarizes the possible potential solution for seizure monitoring using biomarker
detection systems. Briefly, the overall activity of a particular sensor is how precisely it can measure
the vitals such as blood pressure, ECG, temperature, respiratory rate, oxygen saturation level,
and others. For example, the Seizure Monitoring and Response Transducer (SMART) belt is wireless
(Bluetooth enabled) two electrode system (Ag/AgCl) which can measure the electrical conductivity
and breathing pattern. The variation in these two parameters generates a report which is sent to the
smartphone/computer system of the caregiver. The “Team Seize and Assist” in Rice University (Texas,
TX, USA) have successfully developed and positively tested over a number of volunteer students.
Smartwatches by Timex (Timex Group USA, Inc., Middlebury, CT, USA), Polar (Kempele, Finland),
Appscomm (Guangzhou, China), the Fuelband fitness tracker (Nike, Beaverton, OR, USA) and other
leading tech providers monitor the health parameters throughout the period of detection. They are
light, ultra-fast and keep one updated about the situation. The commercially available wireless
smart watches with integrated accelerometer sensors detect 90% of GTCS and have very low false
alarm rates [129]. Epi-care free wrist bands (Medtronic, MN, USA) are so optimized that they do not
respond to everyday movements (eating, talking, or sleeping), however, the convulsions associated
with tonic seizures can be easily detected with GSM-based locations and wireless communication
system. This Danish care technology is clinically tested and included in European first-class medical
devices [130]. Sami app which started as an individual project now helping a number of individuals.
It is a customized program with a wireless video camera, an infrared illuminator for good night
vision and subsequently analyses the videos for the qualified event as seizures or disorder. ZephrTM
(Medtronic, MN, USA) is another remote physiological telemonitoring system with the capability of
respiration, HRV, and fitness measurement with the 3D accelerometer.
The creation of an algorithm which can analyze specific epileptic behaviors based on the recorded
biomarkers is of prime importance. However, because of the similarity in the consequences or
symptoms of epileptic seizures makes it difficult to happen. In this regards, Brain Sentinel’s SPEAC®
(Brain Sentinel, Inc., TX, USA) is a non-invasive monitoring technique specifically developed for the
detection of GTCS, which is placed over the belly of the biceps. It is currently in phase III clinical
trials as a specific sensor for seizure type and is one of the fastest GTCS sensing systems to date.
The inbuilt portable surface EMG (sEMG) in SPEAC® showed equivalence (100%) in the detection
of GTCS compared with the gold standard video EEG system with an average time for alarm is
5.53 seconds and average false alarm of 1.4 per 24 h. It is the first FDA-approved non-EEG- based
seizure monitoring system. The mechanism of detection involves the activation of motor cortices
which is precisely detected by sEMG and reducing the stigma involving complex sensing techniques
for a longer detection period. Quantification of the signals from different epileptic seizures is the next
step in progress for the broad application of this smart tech.
Wearable sensors like Embrace and Embrace 2 watches developed by the Massachusetts Institute
of Technology (MIT, MA, USA) are of great value due to their ability to detect epilepsy seizure
with accuracy. The sensor platform detects the convulsive seizures which involve rapid involuntary
rhythmic movement in a period of few seconds, overall body balance, and have USB as well as
Bluetooth connectivity. It is specific in the measurement of GTCS and tracks the overall activity
of the patient. The loss in consciousness and misbalancing activity of the person is recognized by
the smartwatch, followed by intimation to the caregiver as an alarm system [131,132]. The new
version of the Embrace device can measure temperature, movement, and suppression in brain
waves during epileptic seizures. The variation in vitals under stress resulted in the vibration of
the watch to pre-indicate the possibility of a seizure and if not stopped in time will send an alarm to
pre-registered Embrace phones. Hexoskin body-wearable sensors (Montreal, Canada) are clinically
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validated, can measure precise activities related to cardio, neurology, lungs, pediatrics, body motions
and other disorders. Neuroon (Inteliclinic, SanFrancisco, CA, USA) is an advanced sensing system
which measures brainwaves using an EEG platform for advanced comprehensive sleep analysis of
the patient/person in hand. It is a three gold-coated electrode system integrated with other sensors
such as pulse-oximeter and accelerometer. Neuropace (NeuroPace, Inc., Mountain View, CA, USA)
correlates the cardio rhythms with the activity of the brain. It is believed in neurostimulation holds
great potential for various medical disorders. VNS therapy is another successful three-way seizure
monitoring system involving prevention, response and on-demand mild pulse therapy to the vagus
nerve throughout the day to prevent occurrences of seizures. Such doses either shorten or stops the
ongoing seizures. It is not brain surgery but can deliver an extra dosage of therapy when observing
activated heart rates. On an average 73% of people continue treatment with VSN therapy as per
requirement and tuning of therapeutics and smart dosage technology.
Table 3. Available sensing devices in the market.
Sensor/Product Provider Description Class Ref.
(i) Mobile EEG and
cognitive state software
(ii) B-Alert wireless EEG
(iii) B-Alert integration
(iv) Awake/sleep EEG
Analysis Capabilities
Advanced brain
monitoring, Carlsbad,
CA, USA
Neuro-diagnostics device to
interpret brain and
physiological function
EEG biomarkers
Brain-computer interface
Minimally
Invasive/invasive/wearable/
non-wearable/used for detection as
well as prediction sensor
[133]
Apple Seiz Alarm Apple Inc., Cupertino,CA, USA
Detects motions resembling
to seizure, immediate
intimation, monitoring of
seizure activities, GPS
tracking, and event log
tracking.
Non-invasive/wearable/used for
detection sensor [134]
(i) Embrace
(ii) Embrace 2
Developed at M.I.T.,
MA, USA
Detection of GTCS.
Convulsive seizures. Tracks
the activity, stress and
overall body balance,
water-resistant, uses
Bluetooth, low energy, and
provides USB connectivity
for charging
Non-invasive/wearable/used as
detections and prediction sensor [131,135]
RNS® System
NeuroPace Inc.,
Mountain View, CA,
USA
Responds to heart rhythms
and brain activity
Non-invasive/wearable/used as
detection and prediction sensor [136]
Brain Sentinel’s SPEAC®
Brain Sentinel, Inc.,
Texas, TX, USA
Sensitivity to detect
Generalized Tonic Clonic
Seizures.
Phase III trial
the fastest GTC seizure
alarm on the market
Non-invasive/wearable/used as
detection sensor [137]
(i) Ictal Care365
(ii) EDDI
Ictalcare A/S; Brain
Sentinel, Inc., Texas,
TX, USA
Capture immediately
tonic-clonic seizures wireless
epilepsy alarm
Non-invasive/wearable/used as
detection sensor [138]
SMART: Seizure
Monitoring and Response
Transducer belt
Team Seize and
Assist/RICE,
University (RICE,
University)
Cyberonics Inc.
(Houston, TX, USA)
funded the projet
Detects increased electrical
skin conductance, changes
in respiration rate
Non-invasive/minimally
invasive/wearable/used as
prediction sensor
[139]
Neuroon Inteliclinic, SanFrancisco, CA, USA
Measures eye movements,
pulse, saturation, and brain
waves.
Non-invasive/non-wearable/used
for prediction sensor [140]
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Table 3. Cont.
Sensor/Product Provider Description Class Ref.
(i) CentrePoint insight
watch
(ii) ActiGraph GT9X Link
(iii) wGT3X-BT
(iv) CentrPoint Data hub
(v) ActiLife
ActiGraph, Pensacola,
FL, USA
medical-grade wearable
activity and sleep
monitoring solutions based
on
wearable accelerometry
monitors and a robust
software technology
Non-invasive/non-wearable/used
as detection and prediction sensor [141]
INOpulse®
Bellerophon
Therapeutics, Warren,
NJ, USA
Clinical-stage
biotherapeutics in Phase 2b
clinical trial for the detection
of Pulmonary Hypertension
Non-invasive/non-wearable/used
as prediction sensor [142]
Garmin® Health
Garmin International,
Inc., Olathe Kansas,
KS, USA
Wearable solutions for
clinical trials
Non-invasive/wearable/used as
prediction sensor [143]
Smart Shirts
Hexoskin health
sensors and AI
(Montreal, Canada)
Biometric shirts measuring
heart rate, breathing rate,
active and sleep mode.
Non-invasive/wearable/used as
detection and prediction sensor [144]
(i) Brainpower system
(ii) Mirrorable
(iii) Kinect/webcam and
mood detection solutions
(iv) Sdks & APIs
Affectiva/MIT’s Media
Lab, MA, USA
Emotion measurement
technology.
Facial cues or physiological
responses motor skills rehab
based on Mirror Neurons
research
Non-invasive/non-wearable/used
as detection as well as prediction
sensor
[145]
(i) Basis Peak™ Watches
(ii) Basis Peak™ fitness
and sleep tracker
Basis/Intel/Basis
Science, Inc., San
Francisco, CA, USA
Measuring heart rate,
temperature, skin response,
and eye movement
Non-invasive/wearable/used for
prediction sensor [146]
(i) Vitruvius: Versatile
Interface for Trustworthy
Vital User
(ii) Holst Centre/IMEC
Hobo Heeze BV
(iii) Video Observation
System (VOS)
(iv) Emfit: nocturnal
tonic-clonic seizure
monitor
The Vitruvius Project,
Inc., Oregon, WA, USA
Integrated algorithms, EEG,
EKG, accelerometer, low
consumption of power,
cardio, and video sensors
Non-invasive/non-wearable/used
for prediction sensor [147]
Ricola Living Well WithEpilepsy: Jessica, USA
Standard sensor but
connected to Smartphone
EEG system.
Minimally-invasive/non-wearable/
used as prediction sensor [148]
(i) VNS Therapy
(ii) 103 emipulse1
(iii) 104 Demipulse Duo1
(iv) 105 AspireHC1
(v) 106 AspireSR
Cyberonics, Inc., USA
VNS Therapy has the ability
to not only prevent seizures
before they start but also
stop them if they do
Invasive/wearable/used for
prediction and prohibit sensor [149]
Vigil Aide DCT associates PtyLtd., Australia
Convulsion/epilepsy alarm
operated by one of the
telecommunication
authorities.
Non-invasive/non-wearable/used
as detection sensor [150]
Epi-Care free Danish care, Wexford,Ireland
Tonic-clonic epileptic seizure
sensor worn around the
wrist like a watch. arm’s
movements to the alarm
itself, which constantly
analyzes the movements of
the muscles
Non-invasive/wearable/used as
detection and prediction sensor [151]
(i) Zephyr™
(ii) BioModule™ Devices
(iii) Zephyr™ Sports Bra
(iv) Zephyr™ GPS Units
BioHarness and
(v) OmniSense software
Zephyr Technology
Corporation/Medtronic,
CA, USA
Wearable technology
measuring heart rate,
breathing rate, HRV, posture,
and accelerometer activity,
body temperature, caloric
burn, blood pressure
Non-invasive/wearable/used as
detection and prediction sensor [152]
(i) Cara 3D lite
(ii) Vicon Vue
(iii) Bonita
(iv) Blade motion software
(v) Vicon vero
VICON, California,
CA, USA
A camera system, power,
precise and fast 3D facial
capture solution
Non-invasive/non- wearable/used
as detection sensor [153]
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Table 3. Cont.
Sensor/Product Provider Description Class Ref.
(i) Timex watches
(ii) IRONMAN1 Easy
TrainerTM/M5
(iii) Suunto Quest, Ambit3,
H1, H2, H7, FT1, FT2, Ft60,
FT80, FT40, FT7
(iv) L42B-1216#3467
(v) Apple Inc.
(i) Timex (USA)
(ii) Polar (USA)
(iii) Suunto (Finland)
(iv) APPSCOMM
(Guangzhou, China
C&Q Telecom
Equipment Co. Ltd.)
(v) FuelBand
fitness-tracking
bracelet/apple
watches (USA)
Heart rate reading, wrist
heart rate measurements,
mobile compatibility,
GPS, waterproof
Smartwatches with calling
capability
Dual-core smartwatch
Apple watches
Non-invasive/wearable/used as
detection and prediction sensor [154–157]
(i) Intercall
(ii) Sensalert
(iii) Pressure reducing
mattress: Invacare
Sensorium, UK
Systems and bed
management system. Chair
monitoring system
Non-invasive/non-wearable/used
as detection sensor [158]
(i) SAMi®
(ii) Sami2
(iii) Sami 3
SAMi/HIPASS
DESIGN LLC, CO,
USA
Sleep activity monitor using
video and audio support
remote infrared video
camera is sent to an app that
runs on an iOS device such
as an iPhone or iPod Touch
Non-invasive/non- wearable/used
as detection sensor [159]
Tracking sports gear
Nike
&
Athos and
OMsignal (USA)
Smart shirt design for fitness
tracking by measuring heart
rate, temperature, blood
pressure, and hydration
level
Non-invasive/wearable/used as
detection and prediction sensor [160]
6. Viewpoint and Conclusions
Overall, in order to manage epilepsy, the state-of-art detection systems have remarkable scope for
improvement via adopting a systematic approach (Figure 9). Data analysis, sharing, and discussion are
also of high importance to further research in the field and to optimize medication and in-time response
processes for PoC applications. Such multi-model devices enable seizure data collection and discussion
using specific algorithms to improve overall diseases management. This review explains the causes,
ramification, challenges in diagnosis and sensor-based management of epilepsy. We believe that
novel directional therapy involving a synergistic approach of smart nanotechnology and miniaturized
biosensing system can be a promising and potential future diagnostics tool for early-stage detection and
remediation of epilepsy. The miniaturization of biosensing technology can be very useful especially for
the PoC applications. Effective biosensors at clinical and PoC application levels will further be useful to
develop necessary bio-informatics and pharmacogenomics-based sensors to understand this disorder,
its progression, and ultimately management in a personalized manner. Besides, the specific molecular
targets for detecting polymorphism, target triggering hormones, and biosensor-coupled delivery
mechanism for the drugs, genes, and or cells could make a difference at the molecular hierarchy.
Additionally, biosensor implantation with minimal surgical and non-invasive approaches, along with
newer imaging methodology like calcium imaging can be another approach towards the solution for
epilepsy patients.
In the future, the advancements in wearable gadgets, by the use of nanotechnology to detect
and diagnose epilepsy for real-time analysis, can also be used as a timely reminder for drug influx,
making drug intake timing stress less for proper management of epilepsy. All these concepts may
exceptionally enhance the treatment and research scenario, which can ultimately lead us to cure just
not epilepsy, but also other diseases rooted in the human body, ahead.
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Figure 9. Utilization of a multimodal system for charting and seizure prediction for PoC application.
Hence, the need of the hour is a multimodal device which can synergistically detect various
biomarkers at a given time. The device should be wireless, mobile, hassle-free, light, and can
be carried by the patient themselves. It must be easily wearable like a watch or an anklet, to be
worn always. Miniaturization of the various biosensing techniques and integrating it into one small
device can only take place with the wizardry of nanotechnology. It is the field of nano-technology
only which can provide us an integrated solution to epilepsy cure, remediation, and theranostic
developments. Basically, the collaboration among technological giants (Apple, Nike, Hexoskin,
Neuroon), research institutions (Rice, MIT, and others) and various discussion platforms like
epilepsytalk, is needed in this active period, such as a combination of Garmin wearable’s data capture
and the ActiGraph analytical platform that provides a strong monitoring system. Smart nanosensor-
enabled apparels, headsets, bracelets, and other daily wearables remove the stigma and pain associated
with complex monitoring techniques. The development of newer devices and APPs which collaborated
the already patented products, software, data analysis platforms could only help the caregivers, doctors,
and patients a feeling of relief. As we have established through literature and discussions that timely
detection along with precaution is the key to cure or check the epileptic epidemic. The sensors or
techniques enabled with recent technological advancements, nano-biotechnology, ultra-fast, low power
consuming tech., and compiled data analysis is the key to success for now in neurodegenerative
disorders, such as epilepsy. The clinical validations of the results and FDA approval of devices are
increasing, but still not enough to say that we have conquered this disorder. Such epi-care devices
reduce the frequency of visits to hospitals and long term remote monitoring modality. Thus, the
miniaturization followed by hybridization of sensing techniques can result in the measurement of
specific epileptic seizures based on observing and charting of affected biological markers.
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